http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-540092-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b755982699e3ea5199d569ee5f5344c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 |
| filingDate | 2003-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b95bd7afa9ab68a9e88eab9211fab53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67c50987aeda4ccbf91d5f300935d5f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0795239a206e1a00e7cb28e1e8861ff7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_972c5560ba9721956b37b2cf9c2dccc1 |
| publicationDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-540092-A |
| titleOfInvention | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| abstract | Disclosed is a compound of formula (I) wherein: At least one of the positions 6 or 7 of the quinazoline ring must be substituted by a group A and the remaining positions are optionally substituted by up to three R2 groups; X is N, CH or a C-CN group; R1 is independently aryl or heteroaryl substituted by at least one R6 group and optionally substituted by up to three R5 groups where R5 and R6 are as described in the specification; R2 represents H, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, trifluoromethoxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, optionally substituted as defined; and A is represented by formula (II) wherein: T represents alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl optionally substituted as defined; L is N or a CR4 group where R4 is as defined in the specification; Q is selected from CR3R11R12 or NR11R12 where R3 is the same as R2 above and R11 and R12 are as defined; D represents H, trifluoromethyl, difluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -SO2NR9R7, -C(O)R9, -OC(O)R9 or -C(O)NR7R9 optionally substituted as defined; and The remaining substituents are as defined in the specification. Compounds of the type discloser are EGFR and ErbB2 inhibitors useful in the treatment of hyperproliferative diseases. |
| priorityDate | 2002-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 220.